Table 4.
Allergenicity, antigenicity and solubility prediction of the designed vaccine constructs.
| Constructs | Composition | Complete Sequence of Vaccine Constructs | Antigenicity (Threshold 0.4) | Allergenicity (Threshold -0.4) | Solubility (Threshold 0.45) |
|---|---|---|---|---|---|
| V1 | Predicted CTL, HTL & B-cell epitopes with β defensin adjuvant and PADRE sequence | EAAAKGIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKKEAAAKAKFVAAWTLKAAAGGGSLDFSEVSNVGGGSIEGRPEDPVGGGSKDSSLLNNQGGGSGWPYIGSRSGPGPGALTDLGLLYTVKYPNGPGPGNNQFGTMPSLTLACLGPGPGVWDVKDSSLLNNQFGGPGPGLTSLGLLYTVKYPNLKKSERPQASGVKKIMRKEKRDDKDLQRLRKKPPQVGLSYSQTMKKPNAKTWMDIEGRPEDPVEKKLMRKERRDDNDLKRLRDLKKSLTLACLTKQKKKVVKDAVSLINGLDFSMVKKPNMDDLDKLKNKKKNLLYKICLSGKKDERPGNRNPYKKPGLLSYVIGLLPQGSVITVQKKAKFVAAWTLKAAAGGGS | 0.703 | -0.45 | 0.65 |
| V2 | Predicted CTL, HTL & B-cell epitopes with L7/L12 ribosomal protein adjuvant & PADRE sequence | EAAAKMAKLSTDELLDAFKEMTLLELSDFVKKFEETFEVTAAAPVAVAAAGAAPAGAAVEAAEEQSEFDVILEAAGDKKIGVIKVVREIVSGLGLKEAKDLVDGAPKPLLEKVAKEAADEAKAKLEAAGATVTVKEAAAKAKFVAAWTLKAAAGGGSLDFSEVSNVGGGSIEGRPEDPVGGGSKDSSLLNNQGGGSGWPYIGSRSGPGPGALTDLGLLYTVKYPNGPGPGNNQFGTMPSLTLACLGPGPGVWDVKDSSLLNNQFGGPGPGLTSLGLLYTVKYPNLKKSERPQASGVKKIMRKEKRDDKDLQRLRKKPPQVGLSYSQTMKKPNAKTWMDIEGRPEDPVEKKLMRKERRDDNDLKRLRDLKKSLTLACLTKQKKKVVKDAVSLINGLDFSMVKKPNMDDLDKLKNKKKNLLYKICLSGKKDERPGNRNPYKKPGLLSYVIGLLPQGSVITVQKKAKFVAAWTLKAAAGGGS | 0.630 | 0.010 | 0.67 |
| V3 | Predicted CTL, HTL & B-cell epitopes with HABA adjuvant & PADRE sequence | EAAAKMAENPNIDDLPAPLLAALGAADLALATVNDLIANLRERAEETRAETRTRVEERRARLTKFQEDLPEQFIELRDKFTTEELRKAAEGYLEAATNRYNELVERGEAALQRLRSQTAFEDASARAEGYVDQAVELTQEALGTVASQTRAVGERAAKLVGIELEAAAKAKFVAAWTLKAAAGGGSLDFSEVSNVGGGSIEGRPEDPVGGGSKDSSLLNNQGGGSGWPYIGSRSGPGPGALTDLGLLYTVKYPNGPGPGNNQFGTMPSLTLACLGPGPGVWDVKDSSLLNNQFGGPGPGLTSLGLLYTVKYPNLKKSERPQASGVKKIMRKEKRDDKDLQRLRKKPPQVGLSYSQTMKKPNAKTWMDIEGRPEDPVEKKLMRKERRDDNDLKRLRDLKKSLTLACLTKQKKKVVKDAVSLINGLDFSMVKKPNMDDLDKLKNKKKNLLYKICLSGKKDERPGNRNPYKKPGLLSYVIGLLPQGSVITVQKKAKFVAAWTLKAAAGGGS | 0.650 | -1.004 | 0.63 |